RetroSense Therapeutics To Highlight Contributions To Gene Therapy Research In Upcoming Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a privately-held biopharmaceutical company, today announced that Chief Executive Officer Sean Ainsworth will highlight RetroSense’s contributions to gene therapy research during panel presentations at the NY BIO 2016 Annual Meeting and the Piper Jaffray GenomeRx Symposium.